Immune Tolerance Network (UM1 Clinical Trial Required)

About this opportunity

The purpose of this notice of funding opportunity (NOFO) is to support applications to continue the Immune Tolerance Network (ITN). The primary objective of the Network is to develop tolerogenic therapies for immune-mediated disorders. The three main clinical areas of work are: 1) Allergic diseases and asthma; 2) Autoimmune diseases; and 3) Immune-mediated consequences of transplantation. The core functions of the ITN include designing, conducting, and sharing the results of clinical trials and performing integrated mechanistic studies.

Who can apply

• Native American tribal governments (Federally recognized)
• Independent school districts
• For profit organizations other than small businesses
• Others (see text field entitled "Additional Information on Eligibility" for clarification)
• County governments
• Native American tribal organizations (other than Federally recognized tribal governments)
• Small businesses
• Private institutions of higher education
• Public housing authorities/Indian housing authorities
• Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
• Special district governments
• State governments
• City or township governments
• Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
• Public and State controlled institutions of higher education

Additional eligibility information: Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

Each funder sets its own eligibility, so check the details on their page before you apply.